Movement Disorders
- For Parkinson patients with motor fluctuations ‘A Multicenter Phase 2, double-blind, placebo-controlled, randomized, parallel group study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral UCB0022 in study participants with Advanced Parkinson’s disease’, Sponsor – UCB Pharma
- For Parkinson patients undergoing DBS: ‘Visualization of the STN and GPi for DBS Surgery in Patients with Parkinson’s Disease: VISION Study’. Sponsor – Surgical Information Sciences, Inc.
- For People with early, mild PSP (< 3 years from diagnosis) “ Phase 3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)”, Sponsor – Amylyx Pharmaceuticals.
- For patients with atypical Parkinsonism “Measuring swallowing function in response to levodopa in people with Atypical Parkinsonisms”. Sponsor: UAMS
- For over 60 with Parkinsonism ‘A Randomized Placebo-controlled Trial of Zoledronic Acid for Prevention of Fractures in Patients with Parkinson’s Disease’, Sponsor – Parkinson’s Study Group.
- For anyone with Parkinson: ‘Parkinson Foundation PD GENERation Genetic Registry’. Sponsor – Parkinsons Foundation
- For Parkinson without freezing of gait ‘Motor physiology of Freezing of Gait in Parkinson’s disease’.
- For people with Parkinson who are in a medically underserved area of Arkansas: ‘Comparison of different health care delivery methods in a rural underserved population of People with Parkinson’s Disease.’
- For people with Parkinson, family or caregivers: ‘Impact of access to and utilization of digital resource library on self-efficacy in Neurological Disorders”
- For patients with early, untreated Parkinson Disease: ‘A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson’s Disease’, Sponsor: Inhibikase Therapeutics.
Neuro-degenerative Conditions
- For people with Alzheimer Disease: ‘Alzhemier’s Network for Treatment and Diagnostics (ALZ-NET)
- For people with Multiple System Atrophy or PSP: ‘Measuring swallowing function in response to levodopa in people with Atypical Parkinsonisms’
Epilepsy
- For people with Mesial Temporal Epilepsy: A First in Human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)’, sponsor: Neurona Therapeutics.
- For Adults with epilepsy: ‘A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy’, sponsor: Xenon Pharma.
- For Adults with Primary Genetalized Tonic-clonic Seizures: ‘A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures’, Sponsor: Xenon Pharma.
Multiple Sclerosis
- For Adults with MS on Cladribine: A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study)’, Sponsor: EMD Serono.
Stroke
- For adults with acute stroke or high risk TIA: ‘A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA’, Sponsor: Bayer Healthcare
Neuro-Oncology
- For patients with Neurofobromatosis 1: ‘Evaluating mitochondrial dysfunction in patients with neurofibromatosis type 1’
- For patients with Glioblastoma (MGMT promoter +ve): ‘NRG-BN011 A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma’, Sponsor: National Cancer Institute
- For patients with glioma: ‘Single Patient IND: Vorasidenib Expanded Access in Glioma’, Sponsor: Seiver Pharma
Neuro-muscular Disorders
- For patients with ALS: ‘HEALEY ALS Platform Trial’, Sponsor: NEALS consortium
- For patients with Muscular Dystrophies: ‘Muscular Dystrophy Association Neuromuscular Observational Research (MOVR) Data Hub Protocol’, Sponsor: Muscular Dystrophy Association.